Last edition
News about "Phase 1 clinical studies"
Neurosterix Completes Phase 1 Studies of NTX-253 for Schizophrenia
Neurosterix has completed Phase 1 studies of NTX-253 and plans to begin Phase 2 development; Addex retains a 20 percent equity interest in the company.
Phase 1 Clinical Studies | 09/10/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members